|
Variable
|
n/Na (%)
|
|---|
|
Female
|
107/291 (37)
|
|
Median age; years (IQR)
|
70 (61-81)
|
|
Age group
|
|
15–39 years
|
15/291 (5)
|
|
40–64 years
|
86/291 (30)
|
| ≧65 years |
190 (65)
|
|
BMI
|
|
Normal or Healthy Weight (18.5 – 24.9)
|
139/248 (56)
|
|
Overweight (25.0 and Above)
|
41/248 (17)
|
|
Underweight (Below 18.5)
|
68/248 (27)
|
|
Smoking history
|
132/256 (52)
|
|
Alcohol abuse
|
39/257 (15)
|
|
Preceding influenza
|
11/192 (6)
|
|
Vaccination history of PPSV23
|
16/231 (7)
|
|
Comorbidities
|
202/281 (72)
|
|
Chronic pulmonary disease
|
24/281 (9)
|
|
Chronic heart disease
|
19/281 (7)
|
|
Chronic liver disease
|
19/281 (7)
|
|
Chronic kidney disease
|
17/281 (6)
|
|
Diabetes mellitus
|
34/281 (12)
|
|
Immunocompromised status
|
107/281 (38)
|
|
Hyposplenia/asplenia
|
14/271 (5)
|
|
Autoimmune disease
|
33/281 (12)
|
|
Corticosteroid therapy
|
26/281 (9)
|
|
Malignancy
|
56/281 (20)
|
|
Solid cancer
|
37/281 (13)
|
|
Hematologic cancer
|
17/281 (6)
|
|
Anti-cancer agent
|
22/281 (8)
|
|
Clinical presentation
|
|
Bacteremia without any focus
|
47/291 (16)
|
|
Meningitis
|
46/291 (16)
|
|
Bacteremic pneumonia
|
173/291 (59)
|
|
Othersb
|
25/291 (9)
|
|
Serotype
|
|
PCV13 type
|
135/291 (46)
|
|
PPSV23 type
|
191/291 (66)
|
|
Outcomec
|
|
Fatal
|
57/291 (20)
|
- IQR Interquartile range, BMI Body mass index, PPSV23 23-valent pneumococcal polysaccharide vaccine
- a Number of available answers
- b Others included bacteremic arthritis, bacteremic cellulitis, bacteremic spondylitis bacteremic cholangitis, bacteremic empyema, infected aortic aneurysm and infective endocarditis
- c The case fatality was defined as reporting of death by the case-reporting form at the time of reporting
